CO2019005070A2 - Formulaciones farmacéuticas - Google Patents
Formulaciones farmacéuticasInfo
- Publication number
- CO2019005070A2 CO2019005070A2 CONC2019/0005070A CO2019005070A CO2019005070A2 CO 2019005070 A2 CO2019005070 A2 CO 2019005070A2 CO 2019005070 A CO2019005070 A CO 2019005070A CO 2019005070 A2 CO2019005070 A2 CO 2019005070A2
- Authority
- CO
- Colombia
- Prior art keywords
- pharmaceutical formulations
- pharmaceutically acceptable
- magl
- lipase inhibitor
- acceptable salt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940122357 Monoacylglycerol lipase inhibitor Drugs 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En el presente documento se proporcionan formulaciones farmacéuticas que comprenden un inhibidor de la lipasa de monoacilglicerol (MAGL), o una de sus sales farmacéuticamente aceptables, y al menos un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662423124P | 2016-11-16 | 2016-11-16 | |
US201762545857P | 2017-08-15 | 2017-08-15 | |
PCT/US2017/061871 WO2018093950A1 (en) | 2016-11-16 | 2017-11-15 | Pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019005070A2 true CO2019005070A2 (es) | 2019-05-31 |
Family
ID=62145826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0005070A CO2019005070A2 (es) | 2016-11-16 | 2019-05-17 | Formulaciones farmacéuticas |
Country Status (23)
Country | Link |
---|---|
US (1) | US11273159B2 (es) |
EP (1) | EP3541385A4 (es) |
JP (1) | JP2020500176A (es) |
KR (1) | KR20190085046A (es) |
CN (1) | CN110290791A (es) |
AU (1) | AU2017361254B2 (es) |
BR (1) | BR112019009992A2 (es) |
CA (1) | CA3043609A1 (es) |
CL (1) | CL2019001337A1 (es) |
CO (1) | CO2019005070A2 (es) |
DO (1) | DOP2019000123A (es) |
EC (1) | ECSP19035322A (es) |
IL (1) | IL266522B2 (es) |
JO (1) | JOP20190108B1 (es) |
MA (1) | MA46867A (es) |
MX (1) | MX2019005769A (es) |
NI (1) | NI201900052A (es) |
PE (1) | PE20190919A1 (es) |
PH (1) | PH12019501076A1 (es) |
TN (1) | TN2019000148A1 (es) |
UA (1) | UA124884C2 (es) |
WO (1) | WO2018093950A1 (es) |
ZA (1) | ZA201903101B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013207252B2 (en) | 2012-01-06 | 2016-06-09 | H.Lundbeck A/S | Carbamate compounds and pharmaceutical compositions thereof |
CN107849021A (zh) | 2015-05-11 | 2018-03-27 | 阿比德治疗公司 | 治疗炎症或神经性疼痛的方法 |
CN110291083B (zh) | 2016-11-16 | 2022-06-17 | H.隆德贝克有限公司 | Magl抑制剂的结晶形式 |
JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
JP2020500176A (ja) | 2016-11-16 | 2020-01-09 | ルンドベック ラ ホーヤ リサーチ センター,インク. | 医薬製剤 |
WO2018217805A1 (en) | 2017-05-23 | 2018-11-29 | Abide Therapeutics, Inc. | Pyrazole magl inhibitors |
AU2018323459A1 (en) | 2017-08-29 | 2020-02-20 | H. Lundbeck A/S. | Spirocycle compounds and methods of making and using same |
IL297470A (en) * | 2020-04-21 | 2022-12-01 | H Lundbeck As | Synthesis of a monoacylglycerol lipase inhibitor |
WO2023183900A1 (en) * | 2022-03-25 | 2023-09-28 | Nimbus Lakshmi, Inc. | Tyk2 inhibitor formulations and methods of making the same |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
DK0580860T4 (da) | 1991-04-16 | 2005-03-21 | Nippon Shinyaku Co Ltd | Fremgangsmåde til fremstilling af en fast dispersion |
CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5700410A (en) | 1992-10-16 | 1997-12-23 | Nippon Shinyaku Co., Ltd. | Method of manufacturing wax matrices |
US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
CA2220451A1 (en) | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Methods and compositions for improving digestion and absorption in the small intestine |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
BR0017386A (pt) | 2000-12-18 | 2004-01-13 | Novartis Ag | Combinação terapêutica de amlodipina e benazepril |
US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
CA2476936A1 (en) | 2002-02-20 | 2003-08-28 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
EP1855655A2 (en) | 2005-02-25 | 2007-11-21 | F. Hoffmann-Roche AG | Tablets with improved drug substance dispersibility |
CN101583620B (zh) * | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
EP1938804A1 (en) * | 2006-12-22 | 2008-07-02 | Novartis AG | Pharmaceutical formulation comprising neurokinin antagonist |
FR2938341A1 (fr) | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
CN101530399B (zh) | 2009-04-15 | 2011-01-26 | 江苏中兴药业有限公司 | 一种水飞蓟宾固体自乳化片 |
AU2013207252B2 (en) * | 2012-01-06 | 2016-06-09 | H.Lundbeck A/S | Carbamate compounds and pharmaceutical compositions thereof |
CN104379578B (zh) | 2012-03-19 | 2017-06-09 | 阿比德治疗公司 | 氨基甲酸酯化合物及其制备和使用方法 |
EP2844247A4 (en) | 2012-04-20 | 2015-11-25 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
JP6302923B2 (ja) * | 2012-11-02 | 2018-03-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Cftrが媒介する疾患の処置のための医薬組成物 |
TW201446286A (zh) | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | 抗病毒化合物之固態分散調製劑 |
US9551036B2 (en) | 2013-02-25 | 2017-01-24 | Whitehead Institute For Biomedical Research | Metabolic gene mesenchymal signatures and uses thereof |
JP6647592B2 (ja) * | 2013-07-03 | 2020-02-14 | ルンドベック ラ ホーヤ リサーチ センター,インク. | ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 |
WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
CN103893258B (zh) | 2013-12-05 | 2017-09-29 | 人福医药集团股份公司 | 含有广金钱草总黄酮的口服固体制剂及其应用 |
US10093630B2 (en) | 2014-05-21 | 2018-10-09 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
MX2017011997A (es) | 2015-03-18 | 2018-05-28 | Abide Therapeutics Inc | Carbamatos de piperacina y metodos de preparacion y uso. |
CN107849021A (zh) * | 2015-05-11 | 2018-03-27 | 阿比德治疗公司 | 治疗炎症或神经性疼痛的方法 |
US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
JOP20190106A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
JP2020500176A (ja) | 2016-11-16 | 2020-01-09 | ルンドベック ラ ホーヤ リサーチ センター,インク. | 医薬製剤 |
JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
CN110291083B (zh) | 2016-11-16 | 2022-06-17 | H.隆德贝克有限公司 | Magl抑制剂的结晶形式 |
-
2017
- 2017-11-15 JP JP2019523588A patent/JP2020500176A/ja active Pending
- 2017-11-15 BR BR112019009992A patent/BR112019009992A2/pt unknown
- 2017-11-15 CA CA3043609A patent/CA3043609A1/en active Pending
- 2017-11-15 TN TNP/2019/000148A patent/TN2019000148A1/en unknown
- 2017-11-15 PE PE2019001016A patent/PE20190919A1/es unknown
- 2017-11-15 WO PCT/US2017/061871 patent/WO2018093950A1/en active Application Filing
- 2017-11-15 US US16/349,042 patent/US11273159B2/en active Active
- 2017-11-15 MA MA046867A patent/MA46867A/fr unknown
- 2017-11-15 EP EP17872562.8A patent/EP3541385A4/en active Pending
- 2017-11-15 MX MX2019005769A patent/MX2019005769A/es unknown
- 2017-11-15 CN CN201780083650.9A patent/CN110290791A/zh active Pending
- 2017-11-15 KR KR1020197017143A patent/KR20190085046A/ko active IP Right Grant
- 2017-11-15 AU AU2017361254A patent/AU2017361254B2/en active Active
- 2017-11-15 UA UAA201905622A patent/UA124884C2/uk unknown
- 2017-11-15 JO JOP/2019/0108A patent/JOP20190108B1/ar active
-
2019
- 2019-05-08 IL IL266522A patent/IL266522B2/en unknown
- 2019-05-15 PH PH12019501076A patent/PH12019501076A1/en unknown
- 2019-05-16 DO DO2019000123A patent/DOP2019000123A/es unknown
- 2019-05-16 NI NI201900052A patent/NI201900052A/es unknown
- 2019-05-16 CL CL2019001337A patent/CL2019001337A1/es unknown
- 2019-05-17 ZA ZA201903101A patent/ZA201903101B/en unknown
- 2019-05-17 CO CONC2019/0005070A patent/CO2019005070A2/es unknown
- 2019-05-17 EC ECSENADI201935322A patent/ECSP19035322A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP19035322A (es) | 2019-05-31 |
BR112019009992A2 (pt) | 2019-08-27 |
CN110290791A (zh) | 2019-09-27 |
ZA201903101B (en) | 2020-11-25 |
JOP20190108A1 (ar) | 2019-05-09 |
JP2020500176A (ja) | 2020-01-09 |
NI201900052A (es) | 2019-10-30 |
KR20190085046A (ko) | 2019-07-17 |
EP3541385A4 (en) | 2020-06-24 |
MX2019005769A (es) | 2019-12-05 |
AU2017361254A1 (en) | 2019-06-06 |
IL266522B1 (en) | 2023-03-01 |
JOP20190108B1 (ar) | 2023-09-17 |
US20200188393A1 (en) | 2020-06-18 |
DOP2019000123A (es) | 2019-09-30 |
CA3043609A1 (en) | 2018-05-24 |
PE20190919A1 (es) | 2019-06-26 |
RU2019116688A (ru) | 2020-12-17 |
AU2017361254B2 (en) | 2021-09-23 |
TN2019000148A1 (en) | 2020-10-05 |
PH12019501076A1 (en) | 2019-08-19 |
NZ753526A (en) | 2021-03-26 |
MA46867A (fr) | 2019-09-25 |
EP3541385A1 (en) | 2019-09-25 |
IL266522A (en) | 2019-07-31 |
US11273159B2 (en) | 2022-03-15 |
UA124884C2 (uk) | 2021-12-08 |
WO2018093950A1 (en) | 2018-05-24 |
CL2019001337A1 (es) | 2019-10-04 |
IL266522B2 (en) | 2023-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019005070A2 (es) | Formulaciones farmacéuticas | |
DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
UY36151A (es) | ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?. | |
CO2017013293A2 (es) | Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina | |
CO2017005038A2 (es) | Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma | |
DOP2016000262A (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación | |
CL2017001904A1 (es) | Composición para el tratamiento de enfermedad veno-oclusiva hepática. | |
AR104257A1 (es) | Tableta de ribociclib | |
CL2014000393A1 (es) | Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion. | |
BR112017023225A2 (pt) | inibidor de proteína cinase | |
CR20170314A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
MA55015A (fr) | Formulations pharmaceutiques | |
UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
BR112017001888A2 (pt) | formulações biológicas para instilação intravesical | |
CR20190240A (es) | Formulaciones farmaceuticas | |
MA46642A (fr) | Promédicaments d'inhibiteurs de la kallicréine | |
AR112217A1 (es) | Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta | |
EA201991085A1 (ru) | Фармацевтические составы | |
AR103188A1 (es) | Formulaciones de paracetamol inyectables | |
CR20220587A (es) | Formulaciones farmacéuticas | |
ES2970581T3 (es) | Nuevas formulaciones de comprimido de fosfomicina | |
MX2020004546A (es) | Composiciones farmaceuticas orales de lorazepam resistentes al alcohol. | |
UA45119S (uk) | 1. упаковка для антигельмінтного засобу | |
PL25810S2 (pl) | Butelka | |
PL25907S2 (pl) | Butelka |